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Received February 15, 2016; accepted August 25, 2016AbstractBackground: The aim of this study was to investigate whether mutation in AMP-activated protein kinase (AMPK) subunit genes (PRKAG3-230)
is associated with sporadic, isolated WolffeParkinsoneWhite (WPW) syndrome.
Methods: This study consisted of 87 patients with symptomatic WPW syndrome and 93 healthy controls. PRKAG3-230 genotypes were
determined using real-time polymerase chain reaction assay. Genotype and allele frequencies of PRKAG3-230 between patients with WPW
syndrome and healthy controls were ascertained using chi-square test or Fisher exact test when appropriate.
Results: PRKAG3-230 were genotyped in 87 patients (53 men and 34 women; age¼ 24.4 ± 18.0 years) with WPW syndrome and 93 healthy
controls (57 men and 36 women; age¼ 16.8 ± 4.2 years). There were no significant differences between the two groups in terms of age and
sex. The patients with CG and CGþCC genotypes had a significantly increased risk of WPW syndrome compared with those with GG
genotype [odds ratio (OR)¼ 1.99, 95% confidence interval (CI)¼ 1.01e3.89, p¼ 0.045; OR¼ 1.99, 95% CI¼ 1.04e3.78, p¼ 0.037,
respectively]. The allelic types were not associated with the risk of WPW syndrome. The patients with manifest type with CG and CGþCC
genotypes had a significantly increased risk of WPW syndrome compared with those with GG genotype (OR¼ 2.86, 95% CI¼ 1.16e7.05,
p¼ 0.022; OR¼ 2.84, 95% CI¼ 1.19e6.80, p¼ 0.019, respectively). The patients with right-side accessory pathways with CG and CGþCC
genotypes had a significantly increased risk of WPW syndrome compared with those with GG genotype (OR¼ 3.07, 95% CI¼ 1.25e7.51,
p¼ 0.014; OR¼ 2.84, 95% CI¼ 1.19e6.80, p¼ 0.019, respectively). The allelic types were not associated with the risk of WPW types and
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657K.-P. Weng et al. / Journal of the Chinese Medical Association 79 (2016) 656e660Conclusion: This study shows that PRKAG3-230 may be associated with sporadic WPW syndrome among a Taiwanese population. Further
studies are warranted to elucidate the role of mutations in AMPK subunit genes other than PRKAG3-230 in sporadic WPW syndrome.
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The prevalence of WolffeParkinsoneWhite (WPW) syn-
drome based on the electrocardiogram (ECG) criteria is esti-
mated to be 1e3/1000 individuals.1,2 This syndrome is the
most common cause of supraventricular arrhythmias in Asian
countries and the second most common cause in Western
countries.3 Most patients with WPW syndrome have struc-
turally normal hearts and are sporadic; however, a minority of
cases can be familial4 or involve underlying complicating
diseases, such as Ebstein’s anomaly,5 mitochondrial disease,6
or hypertrophic cardiomyopathy (HCM).7,8 The findings of
Gollob et al8 provided the first strong evidence that mutations
in the gamma (g)-2 regulatory subunit of AMP-activated
protein kinase (AMPK), PRKAG2, are associated with fa-
milial HCM and WPW syndrome. The data by Arad et al9
demonstrated that among patients with PRKAG2 mutations,
cardiac hypertrophy may be caused due to abnormal glycogen
storage, resulting in cardiomyocyte vacuolization. The animal
studies further revealed that the annulus fibrosis, which nor-
mally insulates the ventricles from inappropriate excitation by
the atria, was disrupted by glycogen-filled myocytes.10,11 This
suggests that ventricular pre-excitations could be related to
abnormal glycogen storage in cardiac myocytes.10,11 Vaughan
et al12 found no evidence that mutations in PRKAG2 cause
sporadic, isolated WPW syndrome; however, they did not
exclude the contribution of other AMPK subunit genes to
sporadic accessory pathway formation. WPW syndrome is
reportedly associated with cardiomyopathy in some glycogen
storage disorders, such as Danon and Pompe diseases.13 An
animal study by Milan et al14 demonstrated increased
glycogen content in the skeletal muscle of Hampshire pigs
with PRKAG3 mutation, which is similar to human PRKAG2.
Furthermore, Hudson et al15 reported that the glycogen bind-
ing domain of AMPK binds to glycogen and leads to abnormal
glycogen-containing inclusions when AMPK is overexpressed.
Cheung et al16 demonstrated that PRKAG3, in addition to
being expressed in skeletal muscle, is also expressed in the
heart. Their results also suggested that the activity associated
with the g3 subunit is very low in some tissue extracts such as
heart, but the actual protein expression may be higher.16 It is a
plausible hypothesis that PRKAG3 mutation may be related to
glycogen metabolism in the human heart. According to the
databases of National Center for Biotechnology Information,
there are 1140 single-nucleotide polymorphisms (SNPs) in
homo sapiens in the PRKAG3 locus; therefore, we set the
selection criteria as missense SNP with minor allele frequencyof >20% in a Han Chinese population. Therefore, SNPs
rs692243, rs832678, rs17848621, rs52808491, and
rs59655878 were selected for this study. SNPs rs832678,
rs17848621, rs52808491, and rs59655878 were not identified
in this study because of their complete linkage with rs692243.
PRKAG3-230 (rs692243) confers a Pro71Ala mutation and is
an important variant of R225 mutation in human AMPKg3
subunit.17,18 Costford et al18 reported that R225 mutation has
the same amino acid location as the mutations in the human g2
subunit, which are known to alter AMPK function and cause
WPW syndrome. This led us to investigate whether or not
mutation in PRKAG3-230 is associated with sporadic, isolated
WPW syndrome.
2. Methods
This study consisted of 87 patients (53 men and 34 women;
age¼ 24.4± 18.0 years) with symptomatic WPW syndrome
and 93 healthy controls (57 men and 36 women;
age¼ 16.8± 4.2 years). The patients with symptomatic WPW
syndrome were recruited from our electrophysiology labora-
tory registry of patients with paroxymal supraventricular
tachycardia who had undergone electrophysiological study
from 1990 to 2009. No patient had a family history of WPW
syndrome or a history of associated hypertrophic cardiomy-
opathy. HCM or other cardiac lesion was excluded by two-
dimensional echocardiography (2D-echo) in all patients. We
enrolled those healthy controls without a history of arrhythmia
and who had normal ECG and 2D-echo. Blood samples were
collected for PRKAG3-230 analysis after obtaining informed
consents from the parents of all participants. This study was
approved by the Institutional Review Board of Kaohsiung
Veterans General Hospital. For PRKAG3-230 genotyping,
genomic DNA for genotyping was extracted and purified from
whole-blood samples of all participants using PUREGENE
DNA purification kit, (Gentra Systems, Minneapolis, PA,
USA), according to the manufacturer’s instructions. The ge-
notypes of PRKAG3-230 were detected by the TaqMan real-
time PCR method and subsequently analyzed by ABI
PRISM 7500 Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA) in 96-well format. Polymerase
chain reaction (PCR) reactions were performed in reaction
mixes containing 10 ng DNA, 5 mL 2X TaqMan Universal
PCR Master Mix (Applied Biosystems), 0.5 mL 20X primer/
probe mixture, and ddH2O to a final volume of 10 mL. The
PCR program was set as follows: 95C for 10 minutes, fol-
lowed by 40 cycles of 15 seconds at 92C, and 1 minute at
Table 2
Association of the genotypes with healthy controls and WPW patients.
Genotypes WPW patients
(n¼ 87)
Healthy controls
(n¼ 93)
ORa (95% CI) p
No. (%) No. (%)
PRKAG3
GG 21 (24.1) 36 (38.7) 1.00
658 K.-P. Weng et al. / Journal of the Chinese Medical Association 79 (2016) 656e66060C. A single no template control in each 96-well format was
used for the quality control procedure. The allelic-specific
fluorescence data from each plate were analyzed using the
SDS v1.3.1 software (2005; Applied Biosystems) to auto-
matically determine the genotype of each sample. A 5% of
randomly sampled genotypes were repeated for each locus,
and results were 100% consistent with the initial analysis.CG 51 (58.6) 44 (47.3) 1.99 (1.01e3.89) 0.045
CC 15 (17.2) 13 (14.0) 1.98 (0.79e4.95) 0.145
GG 21 (24.1) 36 (38.7) 1.00
2.1. Statistical analysisCGþCC 66 (75.9) 57 (61.3) 1.99 (1.04e3.78) 0.037
Values in bold font were statistically significant.
CI¼ confidence interval; WPW ¼ WolffeParkinsoneWhite.
a Odds ratios and p-values are estimated by logistic regression.All data are expressed as mean ± standard deviation. De-
mographic data between patients with WPW syndrome and
healthy controls were compared using either chi-square test or
Student t test. Genotype and allele frequencies of PRKAG3-
230 were compared between patients with WPW syndrome
and healthy controls using the chi-square test or Fisher exact
test when appropriate. HardyeWeinberg equilibrium was
evaluated by comparing the observed to the expected genotype
frequencies using a goodness of fit chi-square test. The fre-
quencies were estimated using SAS/Genetics (Version 9.1.3;
SAS Institute, Cary, NC, USA) based on the expectation
maximization algorithm. In addition, multiple logistic regres-
sion was used to evaluate the association between allele types,
and genotypes of PRKAG3-230 with risk of WPW syndrome
by adjusting various confounders, such as sex and age. Odds
ratios (OR) and 95% confidence intervals (CI) were calculated
using logistic regression. A p value < 0.05 was considered
statistically significant. The statistical software package of
SPSS (Version 17.0; IBM SPSS Inc., Chicago, IL, USA) and
SAS/Genetics (Version 9.1.3; SAS Institute Inc., Cary, North
Carolina, USA) were used for all statistical analysis.
3. Results
PRKAG3-230 were genotyped in 87 patients with WPW
syndrome and 93 healthy controls. There were no significant
differences between the two groups in terms of age and sex
(Table 1).3.1. Genotype and allele frequencies of PRKAG3-230
between patients with WPW syndrome and healthy
controlsThe genotype and allele frequencies of PRKAG3-230 be-
tween patients with WPW syndrome and healthy controls are
shown in Table 2. The genotype distributions of healthy controlsTable 1
Comparison of age and sex between healthy controls and WPW patients.
Factory/category WPW patients
(n¼ 87)
Healthy controls
(n¼ 93)
P
No. (%) No. (%)
Age (y), mean± SD 24.4± 18.03 16.8± 4.2 0.539
Sex
Female 34 (39.1) 36 (38.7)
Male 53 (60.9) 57 (61.3) 0.959
SD¼ standard deviation; WPW ¼ WolffeParkinsoneWhite.were in HardyeWeinberg equilibrium ( p¼ 0.939). The patients
with CG and CGþCC genotypes had a significantly increased
risk of WPW syndrome compared with those with GG genotype
(OR¼ 1.99, 95% CI¼ 1.01e3.89, p¼ 0.045; OR¼ 1.99, 95%
CI¼ 1.04e3.78, p¼ 0.037, respectively). The allelic typeswere
not associated with the risk of WPW syndrome.3.2. Genotype and allele frequencies of PRKAG3-230
between patients with different WPW types and locations
and healthy controlsThe genotype and allele frequencies of PRKAG3-230 be-
tween patients with different WPW types and locations are
shown in Table 3. The genotype distributions of healthy con-
trols were in HardyeWeinberg equilibrium ( p¼ 0.939). The
patients with manifest type with CG and CGþCC genotypes
had a significantly increased risk of WPW syndrome
compared with those with GG genotype (OR¼ 2.86, 95%
CI¼ 1.16e7.05, p¼ 0.022; OR¼ 2.84, 95% CI¼ 1.19e6.80,
p¼ 0.019, respectively). The patients with right-side acces-
sory pathways with CG and CGþCC genotypes had a
significantly increased risk of WPW syndrome compared with
those with GG genotype (OR¼ 3.07, 95% CI¼ 1.25e7.51,
p¼ 0.014; OR¼ 2.84, 95% CI¼ 1.19e6.80, p¼ 0.019,
respectively). The allelic types were not associated with the
risk of WPW types and locations.
4. Discussion
Our data suggests that PRKAG3-230 genotypes may be
associated with the sporadic WPW syndrome, especially for
manifest WPW syndrome and right-side accessory pathways.
To the best of our knowledge, this is the first study to inves-
tigate the relationship between sporadic WPW syndrome and
PRKAG3 genetic polymorphisms.
Mutations in PRKAG2 were the first to be shown to be
responsible for a familial WPW syndrome8. Genetic defects in
the PRKAG2 gene lead to a diverse cardiac phenotype of
variable clinical expressivity and are a rare, autosomal domi-
nant disease.8 Vaughan et al12 analyzed PRKAG2 poly-
morphism in patients with sporadic WPW syndrome and
found that PRKAG2 polymorphism does not predispose to
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lecular biology of sporadic WPW syndrome seems different
from that of familial WPW syndrome. However, they did not
exclude the contribution of other AMP kinase subunit genes to
sporadic accessory pathway formation.12 Potentially, this
might have led to the identification of other components of the
kinase complex as new disease genes. It is interesting that
PRKAG3-230 genotypes may be associated with sporadic
WPW syndrome in this series. Our findings could have im-
plications for other AMP kinase genetic polymorphism other
than PRKAG2 responsible for sporadic WPW syndrome.
Experimental studies of familial WPW syndrome associ-
ated with mutations in PRKAG2 have not completely clarified
the pathophysiological consequences.10,11,19 Sidhu et al19 re-
ported that a genetic animal model of WPW with excessive
cardiac glycogen is due to a loss of function of AMPK. In
contrast, Arad el al10 demonstrated that transgenic mutant
mice showed elevated AMPK activity and accumulated large
amounts of cardiac glycogen. Wolf et al11 further showed that
glycogen storage cardiomyopathy and electrophysiological
disorders may be attenuated or significantly reversed by the
direct modulation of AMPK-mediated cardiac metabolism.
These animal studies also revealed that the annulus fibrosis,
which normally insulates the ventricles from inappropriate
excitation by the atria, was disrupted by glycogen-filled
myocytes.10,11 Some glycogen storage disorders, such as
Pompe and Danon diseases, can cause WPW syndrome.13 This
suggests that ventricular pre-excitations could be related to
microscopic atrioventricular connections rather than conven-
tional morphological distinct bypass tracts. A mutation in the
g-3 subunit (PRKAG3) associated with excess glycogen
content is demonstrated in both animal and human
studies.14,17,18 PRKAG3, in addition to being expressed in
skeletal muscle, is also expressed in the heart and is related to
glycogen storage.16 Considerable interest may arise regarding
the possible mechanism to explain the role of gylcogen
deposition in WPW syndrome To date, no study has demon-
strated the unique histologic features of sporadic accessory
pathways. However, we postulate that the relationship of
sporadic WPW syndrome with PRKAG3 polymorphism may
be partly explained by the glycogen storage in cardiac myo-
cytes. Further studies are needed to elucidate the role of
PRKAG3-related glycogen storage in sporadic accessory
pathways.
Some limitations of our study need to be considered. Our
study was a single-center investigation comprising a limited
number of participants. Additionally, our study did not eval-
uate the relationship of other AMP-kinase subunit genes with
sporadic accessory pathway formation. Furthermore, SNPs in
PRKAG3 locus were not completely studied due to the limited
number of participants. In addition, other genes such as
endothelin,20 neuregulin,21 and T-box2,22 which have roles in
the development of the cardiac conduction system and the
atrioventricular ring, may be attractive candidate genes to be
evaluated as contributors to the pathogenesis of sporadic
WPW syndrome. However, further replication studies should
be conducted in the future, with large cohorts in other ethnic
660 K.-P. Weng et al. / Journal of the Chinese Medical Association 79 (2016) 656e660groups, to more widely demonstrate the applicability of these
results in other populations.
In conclusion, the results of this study show that PRKAG3-
230 may be associated with sporadic WPW syndrome in a
Taiwanese population.
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